Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

Phase 3IBI363/TAK-928Positive

AI Analysis

Summary

Innovent Biologics announced an expansion of the Phase 3 MarsLight-11 study of IBI363/TAK-928 to include patients with non-squamous NSCLC, an alpha-biased IL-2/PD-1 bispecific fusion protein for immunotherapy-resistant lung cancer.

Clinical Trial Data

Phase

Outcome Details

Study expansion announced to include patients with non-squamous NSCLC

Importance:5/10

Sentiment:

0.30

Phase 3NSCLCOncologyBispecificIL-2PD-1Study ExpansionImmunotherapy

Related Companies

$TAK

Read the original article

Published by PR Newswire Biotech on September 28, 2026 12:00 AM

Read Original